Comparative Pharmacology
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus MEPIVACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNGOTRACHEAL ANESTHESIA KIT versus MEPIVACAINE HYDROCHLORIDE.
LARYNGOTRACHEAL ANESTHESIA KIT vs MEPIVACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine and tetracaine are sodium channel blockers, inhibiting nerve impulse conduction, providing local anesthesia. Epinephrine is a vasoconstrictor that reduces systemic absorption and prolongs duration.
Mepivacaine hydrochloride is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by binding to sodium channels in the neuronal cell membrane, thereby stabilizing the membrane and preventing depolarization.
4 mL of 4% lidocaine (160 mg) via atomizer or nebulizer for topical laryngotracheal anesthesia, with additional 2 mL aliquots as needed, not to exceed 4.5 mg/kg total dose.
1-2% solution, 5-20 mL local infiltration or nerve block, maximum 400 mg per procedure.
None Documented
None Documented
Lidocaine terminal half-life: 1.5–2 hours (normal hepatic function); prolonged to 3–5 hours in heart failure or hepatic disease. Tetracaine: 2–3 hours.
Terminal elimination half-life approximately 2 hours (range 1.5–3 hours). In neonates and patients with hepatic dysfunction, half-life may be prolonged up to 8–10 hours.
Renal excretion of lidocaine and its metabolites (primarily monoethylglycinexylidide (MEGX) and glycinexylidide (GX)); <10% unchanged. Biliary/fecal excretion minimal (<5%).
Primarily hepatic metabolism via amidase enzymes; ~95% excreted as metabolites in bile and feces, <5% unchanged in urine.
Category C
Category C
Local Anesthetic
Local Anesthetic